Pharmacogenomics Market 2020-2026: Global Size, Top Key Players, Growth, Trends, Demand and Forecast Research

Press Release

Rising demand for various techniques to pinpointing diagnoses down to the subtype of chronic conditions will drive the pharmacogenomics market. Increasing prevalence of several infectious and non-infectious diseases is also one of the major factors boosting the demand for regulated next-generation sequencing-based clinical trial assays and companion diagnostics.

For Sample Copy of this Report Visit @ https://www.orianresearch.com/request-sample/722400

The Global Pharmacogenomics Market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2026. Increasing prevalence of several infectious and non-infectious diseases, rising usage in drug discovery processes are the major factors driving the Pharmacogenomics market. Lack of awareness and lack of consistency in pharmacogenomics products will restrain the market growth during the forecast period.

The screening of known polymorphic drug metabolism enzymes and transporters (DMET) is rapidly becoming routine practice in clinical research. So manufacturers are currently focusing on various approaches to pharmacogenomics analysis to provide rapid and cost-effective solutions for both the screening of known polymorphisms and discovery of novel variants.

On the basis of technology, the market is segmented into microarray, sequencing, polymerase chain reaction, and others. Sequencing dominates the market, especially with the advent of next generation sequencing attributed by high throughput screening, high accuracy and speed.

North America held the largest and the fastest market owing to presence of major key players and strategic collaborations among them. Asia Pacific is also expected to exhibit substantial growth rate after North America due to increased investments in R&D and increasing number of clinical trials.

Some of the key players operating in this market include Affymetrix, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Bayer AG, Merck & Co., Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Myriad Genetics, Inc., and Pathway Genomics Corporation.

Global Pharmacogenomics Industry is spread across 121 pages, profiling 10 companies and supported with tables and figures.

Inquire more or share a question if any before the purchase on this report @ https://www.orianresearch.com/enquiry-before-buying/722400 .

Key Benefits of the Report:

* Global, Regional, Country, Insight Type, and Application Market Size and Forecast from 2014-2026

* Detailed market dynamics, industry outlook with market specific PESTEL, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies

* Identification of key companies that can influence this market on a global and regional scale

* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies

* Detailed insights on emerging regions, Insight Type & Application, and competitive landscape with qualitative and quantitative information and facts

Target Audience:

* Pharmacogenomics providers

* Traders, Importer and Exporter

* Raw material suppliers and distributors

* Research and consulting firms

* Government and research organizations

* Associations and industry bodies

Order a copy of Global Pharmacogenomics Market Report 2018 @ https://www.orianresearch.com/checkout/722400 .

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics , capacity production, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:

* Original Equipment Manufacturer,

* Application Supplier,

* Distributors,

* Government Body & Associations, and

* Research Institute

TABLE OF CONTENT

1 Executive Summary

2 Methodology And Market Scope

3 Pharmacogenomics Market — Industry Outlook

4 Pharmacogenomics Market Technology Outlook

5 Pharmacogenomics Market Therapeutic Application Outlook

6 Pharmacogenomics Market Regional Outlook

7 Competitive Landscape

End of the report

Disclaimer

About Us
Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the world’s most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

 

Leave a Reply

Your email address will not be published. Required fields are marked *